SC 13G











Kura Oncology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

50127T 109

(CUSIP Number)

March 6, 2015

(Date of Event Which Requires Filing of this Statement)



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)


* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




CUSIP No.    50127T 109   13G   Page 2 of 5 Pages



Names of Reporting Persons


Troy Edward Wilson


Check the Appropriate Box if a Member of a Group (see instructions)

(a)  ¨        (b)  ¨






Citizenship or Place of Organization


United States

Number of



Owned by






Sole Voting Power



Shared Voting Power




Sole Dispositive Power



Shared Dispositive Power




Aggregate Amount Beneficially Owned by Each Reporting Person




Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)  ¨



Percent of Class Represented by Amount in Row 9




Type of Reporting Person (see instructions)




Item 1(a).   Name of Issuer: Kura Oncology, Inc.
Item 1(b).   Address of Issuer’s Principal Executive Offices: 11119 N Torrey Pines Rd Ste 125, La Jolla, CA 92037.
Item 2(a).   Name of Person Filing: Troy Edward Wilson
Item 2(b).   Address of Principal Business Office or, if none, Residence: 11119 N Torrey Pines Rd Ste 125, La Jolla, CA 92037
Item 2(c).   Citizenship: United States
Item 2(d).   Title of Class of Securities: Common Stock
Item 2(e).   CUSIP Number: 50127T 109
Item 3.        If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
(a)   ¨   

Brokeror dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)   ¨   

Bankas defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)   ¨   

Insurancecompany as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)   ¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)   ¨    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)   ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)   ¨    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
(h)   ¨    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)   ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)   ¨    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k)   ¨    Group, in accordance with §240.13d–1(b)(1)(ii)(K).
  If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:            


Page 3 of 5 Pages

Item 4.        Ownership
  Amount Beneficially Owned: 2,143,727 shares of Common Stock. This amount includes (a) 1,736,991 shares of restricted common stock and common stock owned by Red Fish Blue Fish Revocable Trust, dated December 31, 2012, 1,166,667 shares of which are subject to a right of repurchase as of December 31, 2015, and (b) 406,736 shares of common stock owned by Araxes Pharma LLC, of which Dr. Wilson is the sole Manager.
(a)   Percent of Class: 10.03%
(b)   Number of shares as to which the person has:

(i)     Sole power to vote or to direct the vote: 0


(ii)    Shared power to vote or to direct the vote 2,143,727


(iii)  Sole power to dispose or to direct the disposition of: 0


(iv)   Shared power to dispose or to direct the disposition of 2,143,727


Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ¨.


Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not Applicable


Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable


Item 8. Identification and Classification of Members of the Group

Not Applicable


Item 9. Notice of Dissolution of a Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: January 27, 2016      

/s/ Troy Edward Wilson

      Troy Edward Wilson

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.


Attention:    Intentional misstatements or omissions of fact constitute Federal criminal violations
(See 18 U.S.C. 1001)